Bernd Hoppe
Directeur/Membre du Conseil chez Oxalosis & Hyperoxaluria Foundation
Profil
Bernd Hoppe is currently the Director at Oxalosis & Hyperoxaluria Foundation.
Previously, he worked as the Vice President-Global Medical Affairs at Dicerna Pharmaceuticals, Inc.
Postes actifs de Bernd Hoppe
Sociétés | Poste | Début |
---|---|---|
Oxalosis & Hyperoxaluria Foundation
Oxalosis & Hyperoxaluria Foundation Medical/Nursing ServicesHealth Services The Oxalosis & Hyperoxaluria Foundation is dedicated to eradicating all forms of hyperoxaluria disease forever. The non-profit company is based in New York, NY. The company's vision is a world without hyperoxaluria, and they are committed to improving the daily lives of people with this condition. | Directeur/Membre du Conseil | - |
Anciens postes connus de Bernd Hoppe
Sociétés | Poste | Fin |
---|---|---|
DICERNA PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA. | Health Technology |
Oxalosis & Hyperoxaluria Foundation
Oxalosis & Hyperoxaluria Foundation Medical/Nursing ServicesHealth Services The Oxalosis & Hyperoxaluria Foundation is dedicated to eradicating all forms of hyperoxaluria disease forever. The non-profit company is based in New York, NY. The company's vision is a world without hyperoxaluria, and they are committed to improving the daily lives of people with this condition. | Health Services |